Trials / Recruiting
RecruitingNCT06988488
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elranatamab | Specified dose on specified days |
| DRUG | Mezigdomide | Specified dose on specified days |
| DRUG | Dexamethasone | Specified dose on specified days |
Timeline
- Start date
- 2025-10-07
- Primary completion
- 2027-05-31
- Completion
- 2027-06-03
- First posted
- 2025-05-25
- Last updated
- 2026-02-02
Locations
22 sites across 8 countries: United States, Canada, China, Germany, Greece, Norway, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06988488. Inclusion in this directory is not an endorsement.